This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M.Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clinical Therapeutics 28: 1935-1946, No. 11, Nov 2006
Rights and permissions
About this article
Cite this article
Solifenacin eases symptom bother, QOL burden in OAB. Pharmacoecon. Outcomes News 522, 9 (2007). https://doi.org/10.2165/00151234-200705220-00028
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705220-00028